Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

Presented here are the 5-year end-of-study results from the pivotal phase 2 trial of brentuximab vedotin in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) after failed hematopoietic autologous stem cell transplantation. At 5 years, the overall patient population (N = 102) had an estim...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Blood Ročník 128; číslo 12; s. 1562
Hlavní autori:	Chen, Robert, Gopal, Ajay K, Smith, Scott E, Ansell, Stephen M, Rosenblatt, Joseph D, Savage, Kerry J, Connors, Joseph M, Engert, Andreas, Larsen, Emily K, Huebner, Dirk, Fong, Abraham, Younes, Anas
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 22.09.2016
Predmet:	Adult Brentuximab Vedotin Female Hodgkin Disease - drug therapy Hodgkin Disease - mortality Hodgkin Disease - pathology Humans Immunoconjugates - therapeutic use Male Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - pathology Neoplasm Staging Prognosis Remission Induction Salvage Therapy Survival Rate
ISSN:	1528-0020, 1528-0020
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!